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Abstract 
Cyclic peptides and peptoids were prepared using the thiol-ene Michael-type reaction. 
The linear precursors were provided with additional functional groups allowing for 
subsequent conjugation: an orthogonally protected thiol, a protected maleimide, or an 
alkyne. The functional group for conjugation was placed either within the cycle or in an 
external position. The click reactions employed for conjugation with suitably 
derivatized nucleoside or oligonucleotides were either cycloadditions (Diels-Alder, 
Cu(I)-catalyzed azide-alkyne) or the same Michael-type reaction as for cyclization. 
 
 INTRODUCTION 
With respect to the linear counterparts, conformationally constrained peptides offer 
increased bioavailability and affinity for the target.1 Cell uptake has been shown to 
increase if cyclization is accompanied by the formation of internal H-bonds, which 
reduces the cost of amide bond desolvation.2,3 Suitably derivatized cyclic peptides can 
be used as scaffolds (cyclic decapeptide RAFT4 is an example) for the assembly of 
different moieties (epitopes, drugs, ligands, labels, etc.) at predetermined positions, 
affording biomolecules with a degree of structural organization much higher than the 
one accessible through derivatization of a linear peptide. Furthermore, cyclic peptides 
hold promise to interfere with protein-protein or protein-RNA interactions (references 
5-7 are some examples of recent publications on these subjects). 
A survey of the latest literature shows that the synthesis of conjugates of cyclic peptides 
is an active subject of research. In a large number of papers the affinity of αVβ3 integrin8 
for RGD-containing cyclic peptides9 (RGD = ArgGlyAsp) is exploited to develop new 
methodologies both for the selective targeting and the imaging of tumor cells/tissues 
and vessels expressing that cell adhesion protein. Additionally, conjugates of cyclic 
peptides with biological interest (immunosuppressive, epitope mimicking, 
antimicrobial, antifungal, or cell penetrating, among others) or nanotube precursors 
have been prepared to improve pharmacological properties10-15 and to investigate new 
materials.16,17 
Amide-linked units form most of these peptides, while some incorporate unnatural 
linkages. As to the conjugation chemistry, formation of peptide bonds and the Michael-
type reaction between a maleimide and a thiol are the most common alternatives, but 
other "click" reactions, and particularly the Cu(I)-catalyzed azide-alkyne cycloaddition, 
are becoming increasingly frequent. 
 There are very few reports on the synthesis and application of [cyclic peptide]-
oligonucleotide conjugates. Hamilton and coworkers18 linked cyclic tetrapeptides to 
guanine-rich oligonucleotides that assembled onto a parallel tetraplex. The distribution 
of the peptide ligands on the vertexes of the top tetrad provided an α-chymotrypsin 
inhibitor that effectively interacted with the protein surface. In a related approach, the 
covalent attachment of peptides to the 5' ends of two guanine-rich oligonucleotides 
provided, in the presence of potassium cations, a parallel G-quadruplex with two loop 
mimics on its surface.19 Cyclic peptides have been covalently linked to the sense strand 
of a siRNA duplex, which facilitated transport of the oligonucleotide through the cell 
membrane and inhibited gene expression.20 More recently, disulfide-containing 
citrullinated peptides have been linked to various oligonucleotides and immobilized on 
plates for diagnostic ELISA assays.21 
In this manuscript we wish to describe methodology allowing for the straightforward 
synthesis of [cyclic peptide]-oligonucleotide conjugates. Model peptides (and a peptoid) 
cyclized using the Michael-type maleimide-thiol reaction22 and incorporating a 
functional group allowing for subsequent conjugation were prepared. Then, 
oligonucleotides were linked to different positions (internal or external) of the cyclic 
polyamide using various click reactions, namely the Diels-Alder and Cu(I)-catalyzed 
Huisgen cycloadditions, or, again, the Michael-type thiol-ene. We believe that easy 
access to [cyclic peptide]-oligonucleotide conjugates will pave the way for new studies 
aiming at assessing whether cyclic peptides facilitate the cell uptake of 
oligonucleotides, and promote interactions with cell machineries different from those 
driven by the linear oligomers. To our knowledge, whether the gene silencing or splice-
switching properties of oligonucleotides linked to cyclic peptides differ from those of 
[linear peptide]-oligonucleotide conjugates has never been assessed. 
  
RESULTS 
As recently described by the group,22 peptides can be cyclized by reaction between a 
maleimide and a thiol. Cyclic peptides can be obtained from linear precursors after the 
TFA treatment that deprotects the peptide chain following stepwise elongation on a 
solid matrix, using S-trityl protected cysteine and a maleimide moiety (Scheme 1A). 
Since the maleimide moiety is labile to nucleophiles such as piperidine, which is used at 
every synthesis cycle to remove the Fmoc temporary protecting group, it can only be 
installed at the N-terminus. For introduction at any other position of the chain the 
maleimide has to be protected, for which purpose an Fmoc-lysine derivative with 2,5-
dimethylfuran-protected 3-maleimido-propanoic acid linked to the ε-amine can be 
used.23 In this case the cyclic peptide is not obtained after the reaction with TFA but 
after the thermal treatment that deprotects the maleimide. 
Cyclic peptides can be derivatized for conjugation in three different ways (see Scheme 
1B). In cyclic peptides types I and II, the functional group for conjugation (depicted as 
a triangle) is outside the cycle, and the cycle involves, respectively, amino acids placed 
at either the N-terminus of the peptide chain (the group for conjugation is then placed at 
the C-terminus) or the C-terminus (and the group for conjugation is at the N-terminus). 
In type III cyclic peptides the group for conjugation is within the cycle. 
Linear precursors incorporating a free and a protected maleimide are needed to 
synthesize maleimido-derivatized cyclic peptides. The free maleimide, which will form 
the cycle, can only be placed at the N-terminal end, while the protected moiety can 
occupy any other position. As stated above, if the protected maleimide is closer to the 
C-terminus than the thiol involved in cyclization, the result is a type I cyclic peptide 
 (Scheme 1C, alternative a). These peptides can be conjugated with either thiol- or diene-
derivatized molecules. 
 
 
Scheme 1. A) General procedure for the synthesis of peptides cyclized using the thiol-
maleimide reaction. B) General structure of the three types of cyclic peptides (or peptoid) 
prepared in this work, derivatized for conjugation. Cyclization was accomplished by a Michael-
type maleimide-thiol reaction in all cases. C) Schematic structure of the cyclic molecules 
showing the functional group for conjugation, and combinations of functional groups (R1, R2 
and R3, suitably protected when required) on the resin-linked peptide/peptoid precursor for each 
of the alternatives tested (a-d). Two of those groups had to react with each other and generate 
the cycle, and the third provided the functionality for conjugation with another molecule (in this 
work, nucleoside or oligonucleotide). Their relative position within the chain determined the 
N
O
O
PEPT*
PEPT*
c)
a)
d)
SH
PEPT*
PEPT*: peptide in alternatives a, b and c; peptoid in alternative d
B)
C)
Type I
Type III
Type III
HS PEPT*b) Type II
PEPT*
N C
PEPT*
N C
PEPT*
N C
Type I Type II Type III
Mal.
Mal. S-Tr Prot. Mal.
Prot. Mal. S-TrAlkyne
S-Tr
S-Tr Prot. Mal.S-PG
S-PG'
PROTECTED PEPT*
R1 R2 R3
N
O
O S
== solid matrix; = reactive function for conjugation
      (maleimide, thiol or alkyne)
;
PG = protecting group
A)
PEPT*PROTECTED PEPTIDE
Maleimide S-Trt
TFA
 type of cyclic molecule that was obtained (I, II or III). Abbreviations: Fm = 9-fluorenylmethyl; 
Mal. = maleimide; Prot. mal. = (2,5-dimethylfuran)-protected maleimide; Tr = trityl. 
 
The precursors of cyclic peptides derivatized with thiols must incorporate two 
orthogonally protected cysteine residues. The cysteine residue involved in cyclization 
can be protected with the trityl group (Scheme 1C, alternatives b and c), but the best 
option to protect the cysteine residue involved in conjugation depends on its position 
within the chain (see below). Both thiol-derivatized cyclic peptides types II and III 
have been prepared, and conjugated with a maleimido-containing compound. 
The use of different reactions for cyclization and conjugation is less complicated from 
the chemical point of view, and has been evaluated with a peptoid chain (peptoid units 
are N-alkylglycines). Even though the thiol-ene reaction is probably much quicker than 
the reduction of azides by thiols,24,25 we preferred not to expose the azide to the 
presence of a free thiol. Hence, an azide-containing molecule was used for conjugation 
with the alkyne-derivatized, type III cyclic peptide. Cyclization can be carried out with 
no risk in the presence of an alkyne (Scheme 1C, alternative d), which will not react 
with either the thiol or the maleimide. 
Peptides were prepared by solid-phase synthesis using the standard Fmoc/tBu 
methodology. All were assembled on the Rink amide MBHA (p-
methylbenzhydrylamine) resin, and were thus obtained as C-terminal carboxamides. 
Acylation with 3-maleimidopropanoic acid after chain elongation allowed a free 
maleimide to be attached to the peptide N-terminus. 
These compounds were conjugated with suitably derivatized oligonucleotides (or 
nucleoside), as shown in Schemes 2-5 in more detail. Diene- and maleimido-containing 
oligonucleotides (dT5, dT = 2'-deoxythymidine) were synthesized following described 
procedures.26,27 
 Schemes 2, 3 and 4 illustrate in more detail the different steps required to obtain cyclic 
peptides types I to III, and the corresponding conjugation products. 
 
Synthesis and conjugation of a type I cyclic peptide 
In the first alternative (aimed to provide type I cyclic peptide, a in Scheme 1B), the 
fully protected peptide precursor (1) incorporated two maleimides, one free (at the N-
terminus) and one protected (at the C-terminus), and a trityl-protected cysteine residue 
(Scheme 2). Therefore, the TFA treatment that was carried out after assembly of the 
linear precursor removed all protecting groups except that on the C-terminal maleimide, 
and, as previously described,22 furnished the partially protected cyclic peptide 2. 
Maleimide thermal deprotection (retro-Diels-Alder reaction) was performed 
subsequently in the presence of 5'-diene-dT5, which afforded the target conjugate 3. 
 
 
Scheme 2. Synthesis of type I cyclic peptide 2 and conjugation with oligonucleotide dT5. 
Abbreviations: Pbf = 2,2,4,6,7-pentamethyldihydro-benzofuran-5-sulfonyl. 
 
Synthesis and conjugation of a type II cyclic peptide 
The goal of the second alternative (b in Scheme 1B) was to obtain a peptide with a free 
thiol group for conjugation at the N-terminus of the chain (type II cyclic peptide). This 
 required a precursor with two differently protected cysteines and a protected maleimide 
(Scheme 3). The cysteine that had to participate in cyclization was protected with the 
TFA-labile trityl group, and it was necessary to assess which thiol protecting group was 
suitable for the other cysteine. This group had to remain stable during the treatments 
required to obtain the cycle, that is, TFA treatment and maleimide deprotection. 
 
a) 
 
  
b) 
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Scheme 3. Assays carried out to obtain cyclic peptide 16 (type II, alternative b in Scheme 1) 
using different thiol protecting groups for the N-terminal cysteine (the one to be involved in 
conjugation). a) Deprotection of the maleimide of peptide 5 afforded two products, 6 and 7, in 
similar ratio. The latter furnished conjugate 8 by reaction with diene-dT5. b) Removal of the 
Acm cysteine protecting group from 11 yielded complex mixtures of products in all the 
conditions tested. c) Cyclic peptide 16 was prepared by combining Tr and Fm as cysteine 
protecting groups, and conjugated with maleimido-dT5. Abbreviations: Acm = 
acetamidomethyl; Fm = 9-fluorenylmethyl. 
 
We first evaluated the possibility of protecting the side chain of the N-terminal cysteine 
with the StBu and acetamidomethyl groups, whose Fmoc derivatives are commercially 
available and which are TFA-stable (Schemes 3a and 3b). In preliminary experiments 
both Fmoc-Cys(StBu)-OH and Fmoc-Cys(Acm)-OH proved to be stable to maleimide 
deprotection conditions (heating in a microwave oven a solution of the compound in 1:1 
MeOH/H2O for 90 min at 90 oC). Yet, when peptide 5 was submitted to these reaction 
conditions, two products were obtained (Scheme 3a): the target compound (6) with the 
thiosuccinimide-containing cycle, and a peptide (7) with a disulfide bridge and a free 
maleimide (the 6:7 ratio was 1:1 when the peptide was heated for 30 min, and 3:2 when 
 the reaction was extended to the 90 min typically required for full maleimide 
deprotection27). 
Mass spectrometric analysis confirmed presence of the StBu group in 6, its loss after 
reaction with tris(2-carboxyethyl)phosphine (TCEP) to yield 16 (see structure in 
Scheme 3c), and loss of the three N-terminal amino acids when 6 was digested with 
thrombin. Instead, the mass of 7 was lower than that of 6, and the product remained 
undigested upon treatment with thrombin. Final confirmation of the presence of a free 
maleimide in 7 was obtained from reaction with diene-dT5, which afforded the 
[disulfide cyclic peptide]-oligonucleotide conjugate 8. As expected, the Diels-Alder 
reaction is fully compatible with the presence of the disulfide. Even though the thiol-
maleimide reaction slightly predominated over disulfide formation, the relative amounts 
of the products obtained after maleimide deprotection are too similar to consider this 
alternative a good synthetic method. 
In the second group of assays (Scheme 3b) the N-terminal cysteine was protected with 
the acetamidomethyl (Acm) group. Here the problem was that none of the conditions 
tested for its deprotection (reactions with either Ag+, iodine, or Tl3+) provided clean 
crudes with the target cyclic peptide (16) as the main product (see Supporting 
Information). 
We next evaluated the combination of protecting groups shown for peptide-resin 12 
(Scheme 3c), using commercially available N-Boc-Cys(Fm)-OH. In this case treatment 
with TFA deprotected the N-terminus and the other functional groups, except those on 
the N-terminal cysteine and the maleimide, to yield 13. Maleimide deprotection and the 
thiol-maleimide reaction that furnished the cycle (14) took place simultaneously, and, as 
described in the literature,28 treatment with piperidine removed the Fm protecting group 
and provided the disulfide (15). The cyclic peptide with the free thiol (16) was obtained 
 after reduction with TCEP, and subsequent reaction with maleimido-dT5 afforded 
conjugate 17. Hence, the 9-fluorenylmethyl group is fully compatible with maleimide 
deprotection and peptide cyclization by the Michael-type thiol-ene reaction. Even 
though removal of the Fm group is accompanied by thiol to disulfide oxidation, which 
adds a reduction step, this group is suitable to mask the cysteine side chain provided 
that the so-protected cysteine is placed at the N-terminus. Peptide elongation using the 
Fmoc/tBu approach rules out any other possibility. 
 
Synthesis and conjugation of type III cyclic polyamides (peptide and peptoid) 
Two different type III cyclic polyamides were synthesized (alternatives c and d in 
Scheme 1B). Here the functional group for conjugation appended from a residue placed 
within the cycle. In one case the polyamide was a peptide and the functional group for 
conjugation a thiol (20), while in the other it was a peptoid derivatized with an alkyne 
(24). 
Scheme 4 depicts the preparation and conjugation of cyclic peptide 20. The C-terminal 
cysteine was protected with the trityl group, which reacted with the N-terminal, free 
maleimide upon treatment with TFA. Under these conditions the free thiol gave the 
Michael-type reaction and left untouched the internal, StBu-protected cysteine residue. 
In other words, the free thiol reacted much faster with the maleimide than with the 
StBu-protected cysteine. The side chain of the internal cysteine of the cyclic peptide 
(19) was deprotected by reaction with TCEP and, after purification, reacted with 5'-
maleimido-dT5 to yield conjugate 21. 
 
  
Scheme 4. Steps involved in the preparation of cyclic peptide 20 and conjugate 21. 
 
Scheme 5 shows the preparation of a cyclic peptoid and the structure of the derived 
conjugate. On-resin assembly of the peptoid was carried out using the submonomer 
procedure,29 also on the Rink amide MBHA resin. As shown in the upper part of the 
scheme, chain elongation involves two subsequent steps, namely acylation with 
bromoacetic acid and reaction with an amine. Three of the amines required to 
synthesize peptoid 23 were commercially available (see list at the Supporting 
Information), and S-Tr-protected cysteamine and N-Boc-1,2-diaminoethane were 
prepared following described procedures.30,31 Cyclization with an N-terminal maleimide 
required incorporation of a maleimide-containing monomer, and 3-maleimidopropanoic 
acid is the cheapest alternative. However, since we had observed that the quality of 
 cyclic peptide crudes was a bit lower when cyclization took place upon treatment with 
TFA,22 we incorporated the 2,5-dimethylfuran-protected maleimidopropanoic acid.27 To 
introduce maleimide moieties at other positions of the chain, 2-[(2,5-dimethylfuran-
protected) maleimide]-1-aminoethane23 should be employed. In the absence of two 
orthogonal maleimide protecting groups, this precludes use of maleimides for 
subsequent conjugation. 
 
 
Scheme 5. Synthesis of cyclic peptoid 24 and conjugate 25. 
 
Chain assembly furnished the fully protected peptoid 22, from which all protecting 
groups except that on the maleimide were removed by treatment with TFA. Maleimide 
deprotection and cyclization took place simultaneously to afford 24. Finally, the Cu(I)-
 catalyzed Huisgen reaction between cyclic peptoid 24 and AZT (2',3'-dideoxy-3'-
azidothymidine) provided the target conjugate (25). The azide-containing molecule was 
in this case a simple nucleoside analog, but the high success of the Cu(I)-catalyzed 
alkyne-azide cycloaddition has prompted many groups to develop methodology for the 
preparation of azide-derivatized oligonucleotides (see, for instance, references 32-34) 
circumventing the incompatibility between azides and phosphite-based reagents.35,36 
 
DISCUSSION 
We have shown that, by adequately combining differently protected cysteines, free and 
protected maleimides, and an alkyne, and choosing their relative position in the chain, it 
is possible to easily obtain cyclic peptides derivatized with a functional group allowing 
for subsequent conjugation, for instance with oligonucleotides. 
In all cases cyclization was carried out using the thiol-ene Michael-type reaction. For 
this purpose, in all peptide precursors one of the cysteine residues was masked with the 
TFA-labile trityl group, so that the acidic treatment that follows chain elongation 
deprotected its thiol. When a free maleimide had been appended to the N-terminus of 
the chain, this unmasked thiol reacted with the maleimide to form the cycle (peptides 2 
and 19) during the TFA deprotection step.22 Whenever a masked maleimide was 
incorporated into the chain, an additional deprotection step was required. Then, thermal 
removal of the maleimide protecting group (retro-Diels-Alder reaction) and cyclization 
took place simultaneously (peptide 14 and peptoid 24). 
As required for conjugation with a suitably derivatized molecule, cyclic peptides had to 
incorporate an additional functional group. In this work, this group was either a 
maleimide, a thiol, or an alkyne. 
 With the cyclization strategy that we have used, the only possibility to use a maleimide 
for conjugation is to assemble a peptide precursor with a free maleimide at the N-
terminus (to form the cycle) and a protected maleimide at any other position. Placing 
the lysine carrying the protected maleimide at the C-terminus (as in 1) furnishes type I 
cyclic peptides, with amino acids out of the cycle and the maleimide for conjugation at 
the C-terminal end. It is reasonable to surmise, on the basis of the results here described, 
that placing that lysine within the cycle will successfully provide cyclic peptides with an 
internal maleimide for conjugation. Maleimide-derivatized cyclic peptides (and any 
maleimide-containing compound) can be conjugated with diene-derivatized molecules, 
as in the synthesis of 3, where maleimide deprotection and conjugation took place 
simultaneously. It is also worth mentioning that, even though the proof of principle 
experiments here described were carried out with simple oligonucleotide sequences, the 
compatibility of oligonucleotides of different length and composition27 with the reaction 
conditions in which maleimides are deprotected suggests that any oligonucleotide can 
be linked to cyclic peptides. Alternatively, maleimide-derivatized cyclic peptides could 
be conjugated with thiols. 
When the cyclic peptide is to be derivatized with a thiol for conjugation, the choice of 
protecting group for the cysteine providing this thiol depends on its position in the 
chain. If the goal is a type II cyclic peptide, the best alternative among those we have 
examined is to block the thiol with the Fm group, which is compatible with maleimide 
deprotection and cyclization and can be removed with no formation of byproducts. The 
only drawback is that removal of the Fm group by reaction with piperidine is 
accompanied by disulfide formation, an additional reduction step being thus necessary 
prior to conjugation. N-Terminal derivatization of a peptide with a thiol was here 
accomplished by introducing either suitably protected cysteine residue, but an S-blocked 
 mercaptoacetic acid should also work. Use of cysteine derivatives has the advantage 
that the amino function can be further derivatized, allowing for the attachment a 
fluorophore, for instance, or any reporter group. 
Conversely, the synthesis of cyclic peptides with the cysteine that provides the thiol for 
conjugation at any other position of the chain (not at the N-terminus) is much more 
straightforward (this is the case of type III peptide 20, but the same protection scheme 
could provide type I peptides). That cysteine can indeed be protected with the StBu 
group, which remains stable during the acidic treatment that removes most of the 
protecting groups from the peptide and does not react with the free thiol resulting from 
the deprotection of Cys(Tr) (or if it does, the extent of the reaction is negligible). As 
stated before, at room temperature and under these strongly acidic conditions, formation 
of the cycle by reaction between the free thiol and the free maleimide is much quicker. 
Yet (see above and Scheme 3a), this is not the case when the peptide has to be heated. 
Thiol-derivatized cyclic peptides can be conjugated with maleimido-oligonucleotides, 
as in the case of 17 and 21. 
Type III cyclic peptoids derivatized for conjugation by the Cu(I)-catalyzed Huisgen 
cycloaddition were also synthesized. In this case the key monomers were 3-(2,5-
dimethylfuran-protected)maleimidopropanoic acid,27 S-trityl-cysteamine30 and 
propargylamine. Use of S-Fm-cysteamine instead of propargylamine would provide 
peptoids cyclized by the thiol-maleimide reaction and derivatized with a thiol group for 
conjugation. 
As to the use of alkynes for conjugation, the triple bond can be installed at any position 
of the polyamide chain. It is neither affected by any of the peptide/peptoid synthesis 
reagents, nor by the thiol-maleimide cycle-forming reaction. We have prepared a [cyclic 
peptoid]-nucleoside conjugate to verify that synthesis proceeded as expected, and the 
 triple bond was introduced in an internal position by reacting propargylamine with the 
haloacylated resin-linked, growing peptoid chain. Commercially available alkyne-
containing L-amino acids or alkynoic acids allow triple bonds to be attached to peptides 
in a straightforward manner, which is also the case for derivatization with azides. 
 
CONCLUSIONS 
In summary, we have broadened the scope of applications of peptides cyclized making 
use of the maleimide-thiol reaction by introducing an additional group that allows for 
conjugation with oligonucleotides (or other molecules) utilizing click reactions, and 
shown that this methodology can also be employed with peptoids. The method here 
described is based on the adequate choice of protection for maleimides and thiols, as 
well as suitably placing maleimides, thiols or alkynes within the peptide/peptoid chain. 
These synthetic alternatives could also provide other cyclic polyamide scaffolds 
derivatized for conjugation, such as peptide nucleic acids. 
It has been reported that subtle differences in the conjugation chemistry may have 
considerable impact on the biological outcome.37-39 Therefore, it is of interest to develop 
chemical tools giving access to differently linked conjugates. This manuscript describes 
methodology allowing oligonucleotides to be linked to cyclic peptides, either to an 
internal position, or to any of the two ends of a chain in which only some of the residues 
of the peptide are part of a chemically stable cycle. Both cyclic peptides and 
oligonucleotides (natural or modified) are relevant chemical goals that hold promise 
from the therapeutic and diagnostics point of view. So far there is lack of information as 
to the differential effect of linking oligonucleotides to cyclic peptides rather than the 
linear counterparts. Work on this subject is now in progress in the group, and results 
will be published in due time. 
  
EXPERIMENTAL SECTION 
General Methods.  
Peptide synthesis. All peptides were assembled on the Rink Amide resin, which was 
treated and washed with DCM (3 ×), DMF (3 ×), 20 % piperidine/DMF (2 × 15 min), 
DCM (3 ×), DMF (3 ×) and MeOH (3 ×) prior to chain elongation. Incorporation of the 
first amino acid on the solid matrix and peptide elongation were carried out using 3 
equiv. of Fmoc-amino acid, HOBt·H2O and DIPC (DIPC = N,N'-
diisopropylcarbodiimide) dissolved in the minimum amount of DCM and a few drops of 
DMF (90 min), which was followed by washing with DCM, DMF and MeOH (3 ×). In 
case the coupling was not complete, as assessed by the Kaiser test, it was repeated using 
2 equiv. of the reagents. Fmoc groups were removed by reaction with 20 % 
piperidine/DMF (1 × 3 min + 1 × 10 min), followed by washing (DMF, DCM). 
Activation of 3-maleimidopropanoic acid was carried out with DIPC (90 min reaction 
time). Even though activation with DIPC and HOBt·H2O seems not to cause any harm 
on the maleimide, use of only the carbodiimide is safer to prevent addition of HOBt to 
the maleimide of maleimidopropanoic acid). 
Reaction with a TFA/H2O/TIS mixture at room temperature cleaved the peptide from 
the resin and removed most permanent protecting groups (see below and Schemes 2-4 
for details). Filtrate and washings (DCM) were collected and concentrated under a N2 
stream, and cold diethyl ether was added to the resulting oil. The mixture was 
centrifuged (10 min, 5 oC, 4800 rpm) and decanted. This procedure was repeated 3 
times. Peptides were quantified by UV spectroscopy, from the absorbance of tyrosine 
residues at 280 nm (ε280 M-1cm-1 = 1480). 
 Peptoid synthesis. Peptoid 22 was also assembled on the Rink Amide resin, which was 
treated and washed as described above for peptide synthesis. For the acylation step, 
bromoacetic acid (25 equiv.) was dissolved in anh. DMF in a round-bottom flask, the 
solution was cooled to 0 ºC, and DIPC (25 equiv.) was added dropwise. After 5 min, the 
solution was poured onto the resin in the syringe, and the mixture was stirred (shaker) 
under an Ar atmosphere for 45 min. The resin was filtered and washed (DCM, DMF, 
iPrOH and DCM, 3 × each), and the amination step was carried out by reaction with the 
corresponding amine (20 equiv.) dissolved in anh. NMP (500 µL) for 3 h. After this 
reaction the resin was washed again (DCM, DMF and MeOH, 3 × each). Cleavage from 
the resin and removal of most permanent protecting groups was accomplished by 
reaction with TFA at room temperature (see details below, and Scheme 5), which was 
followed by washings with the cleavage mixture and DCM. Solvents and reagents were 
removed from the filtrate by means of a N2 stream until the solution became an oil. 
Cold diethyl ether (10 volumes) was added, and the mixture was centrifuged (10 min, 5 
ºC, 4800 rpm) and decanted. The ether addition plus centrifugation procedure was 
repeated 3 times. The crude was analyzed and purified by HPLC, quantified by UV 
spectroscopy (phenoxy group: ε270 (M-1cm-1) = 1450), and characterized by mass 
spectrometry. 
HPLC. Unless otherwise stated, the following conditions were used: 
- semipreparative HPLC, acidic conditions: Jupiter Proteo column; 3 mL/min; solvent 
A: H2O + 0.1% TFA; solvent B: ACN + 0.1% TFA 
- analytical HPLC, acidic conditions: Phenomenex C18, 4 µm, Jupiter Proteo column; 1 
mL/min; solvent  A: H2O + 0.045% TFA); solvent B: ACN + 0.36% TFA 
 - analytical HPLC (also used for purification at a small scale), buffered medium: 
Kromasil C18, 10 µm column; 1 mL/min; solvent A: 0.05 M TEAA (triethylammonium 
acetate) in water; solvent B: 1:1 H2O/ACN. 
MW-Promoted polyamide deprotection and cyclization. The [protected maleimido]-
containing polyamide was dissolved in a 1:1 (v/v) MeOH:H2O mixture at a 
concentration between 25 and 100 µM in a microwave flask. The flask was sealed and 
heated in the microwave oven (Biotage InitiatorTM Classic) at 90 ºC for 90 min (with 
stirring and internal probe for temperature monitoring). Methanol was then removed 
under reduced pressure and the resulting aqueous solution was analyzed by HPLC. 
Alternatively, methanol removal was followed by lyophilization, and the crude was 
redissolved in water for HPLC analysis. 
Assessment of cyclization: Reaction with H2O2. Formation of a cyclic product was 
confirmed by reacting the peptide, either linear or cyclic, with a dilute solution of H2O2 
(3.5%) for 1 h, and subsequent MS analysis.23 When the peptide is linear, H2O2 oxidizes 
the free thiol to sulfonic acid (and the mass increases 48 units), whereas when the 
peptide is cyclic the thioether is oxidized to sulfoxide (and the mass increases 16 units). 
This method cannot be used when the peptide to be analyzed incorporates a Cys(StBu) 
residue, because this disulfide is oxidized to different products. ESI Mass spectrometric 
analysis showed formation of mixtures of products with and without loss of the StBu 
group. When analysis was performed in the negative mode, the main group of peaks 
corresponded to loss of the StBu group and oxidation of the thiol to sulfonic acid (+ 3 
oxygen atoms, M+48). 
Assessment of cyclization: Digestion with thrombin. Reaction with thrombin can also be 
used to assess circularity. Thrombin cleaves the Arg-Gly bond in linear GRG peptide 
sequences, but not when this sequence is within a cycle. 20 µg of peptide and 5u of 
 thrombin, dissolved in a 1:2 PBS:H2O solution (PBS buffer: 140 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4 and 1.8 mM KH2PO4, pH = 7.23), were incubated at room 
temperature overnight. The crude was readily analyzed by MALDI-TOF MS. 
Deprotection of Cys(StBu) and reduction of disulfide bridges. TCEP (500 equiv) was 
added to a 0.3 mM solution of the polyamide in H2O (1-3 mL). The pH was adjusted to 
5 with an aqueous dilute NaOH solution, and the mixture was stirred at room 
temperature for 3 h. Water was removed by lyophilization and the crude analyzed by 
HPLC. 
Diels-Alder cycloadditions. The maleimido- or protected maleimido-containing peptide 
and diene-dT5 were dissolved in water, and the amounts required to carry out the 
reaction (typical reagent ratio was 1:1) were taken from each of these solutions and 
mixed. This mixture was diluted with water (or water and methanol, to end up with a 
1:1 proportion, if MW-promoted maleimide deprotection and conjugation were to take 
place simultaneously) to reach a reagent concentration between 30 and 300 µM. The 
maleimide+diene mixture was reacted overnight at 37 ºC. The [protected 
maleimide]+diene mixture was reacted in a MW oven for 90 min at 90 oC. Solvents 
were removed by evaporation under reduced pressure and/or lyophilization, and 
reaction crudes were analyzed by HPLC. Conjugates were purified by HPLC and 
characterized by MALDI-TOF MS. 
Michael-type reactions. Aliquots of aqueous solutions containing the required amounts 
of maleimido-containing compound and the corresponding thiol derivative were mixed 
(final concentration of polyamide: 50-150 mM). The mixture was stirred at room 
temperature under an Ar atmosphere overnight. After lyophilization, reaction crudes 
were analyzed by HPLC. Conjugates were purified by HPLC and characterized by 
MALDI-TOF MS. 
 Assays to assess the stability of cysteine derivatives to microwave-promoted maleimide-
deprotection conditions. The stabilities of Fmoc-Cys(StBu)-OH, Fmoc-Cys(Acm)-OH 
and Boc-Cys(Fm)-OH were assessed by dissolving some 5-10 mg of the product in 
MeOH:H2O 1:1 (v/v), and heating the resulting solution at 90 ºC for 90 min in the 
microwave oven. Solvent was removed under reduced pressure and the crude was 
analyzed 1H NMR. In all cases a spectrum with the same set of signals as for the 
commercial compound was obtained, with one exception: partial loss of the tBu signal 
in the case of Boc-Cys(Fm)-OH, due to partial loss of the Boc group upon heating. 
 
Cyclic maleimido*-Lys-Gly-Arg-Gly-Cys*-Tyr-Ala-Tyr-Lys(Prot.Mal.)-NH2, 2 (the 
label * refers to the units linked in the cycle). Peptide 2 was assembled on 110 mg of 
resin (f = 0.65 mmol/g). Treatment of peptide-resin 1 with TFA/TIS/H2O 90:5:5 (TIS = 
triisopropylsilane), 2 × 1 h, followed by purification at the semipreparative scale (linear 
gradient from 15 to 35% of B in 30 min, tR = 15.1 min), afforded 2 as a white solid 
(12.1 µmol, 17%). Analytical HPLC: acidic conditions, linear gradient from 10 to 50% 
of B in 30 min, tR = 16.2 min. MALDI-TOF MS (DHB, positive mode): m/z 1347.4 
[M−furan+H]+, 1369.4 [M−furan+Na]+; M calcd for C66H91N17O18S 1441.6; M−furan 
calcd for C60H83N17O17S 1345.6. MALDI-TOF MS after reaction with H2O2 (DHB, 
positive mode): m/z 1362.8 [M−furan+16+H]+; M−furan+16 calcd for C60H83N17O18S 
1361.6. MALDI-TOF MS after digestion with thrombin (DHB, positive mode): m/z 
1347.3 [M+H]+ 1369.3 [M+Na]+, 1385.2 [M+K]+; M calcd for C66H91N17O18S 1441.6, 
M−furan calcd for C60H83N17O17S 1345.6. No digestion was observed. 
 
Conjugate 3, [cyclic maleimido*-Lys-Gly-Arg-Gly-Cys*-Tyr-Ala-Tyr-Lys(Mal.)-
NH2] + [diene-dT5]. Diene-dT5 and 2 (15 nmol each) were reacted in a 1:1 MeOH:H2O 
 solution (500 µL, 30 µM) in a MW oven for 90 min at 90 oC. HPLC Analysis of the 
crude showed that the extent of the cycloaddition was 90%. Analytical HPLC: buffered 
medium, gradient from 5% to 60% of B in 30 min, tR = 22.3 min. MALDI-TOF (THAP, 
negative mode): m/z 2962.7 [M−H]-; M calcd for C116H158N27O53P5S 2963.9. 
 
H-Cys(StBu)-Gly-Arg-Gly-Cys-Tyr-Ala-Tyr-Lys(Prot.Mal.)-NH2, 5. Fmoc-
Cys(StBu)-OH was incorporated onto 121 µmol of Fmoc-Gly-Arg(Pbf)-Gly-Cys(Tr)-
Tyr(tBu)-Ala-Tyr(tBu)-Lys(Prot.Mal.)-resin, and the Fmoc group removed to yield 4. 4 
Was deprotected and cleaved by reaction with TFA/TIS/H2O 95:2.5:2.5, 2 × 1 h, and 
purified at the semipreparative scale (linear gradient from 25 to 50% of B in 30 min, tR 
= 9.6 min). A white solid corresponding to the desired peptide (5) was obtained (28 
µmol, 23%). Analytical HPLC: acidic conditions, linear gradient from 5 to 50% of B in 
30 min, tR = 22.7 min. MALDI-TOF MS (DHB, positive mode): m/z 1258.9 
[M−furan+H]+; M calcd for C60H87N15O15S3 1353.6, M−furan calcd for C54H79N15O14S3 
1257.5. MALDI-TOF MS after reaction with H2O2 (DHB, negative mode): m/z 1216.6 
[M−furan−StBu+48−H]-, 1264.5 [M−furan−StBu+48+48−H]-; M+48 calcd for 
C60H87N15O18S3 1401.6, M−furan−StBu+48 calcd for C50H71N15O17S2 1217.5. MALDI-
TOF MS after digestion with thrombin (DHB, positive mode): m/z 876.4 
[M−furan−[Cys(StBu)-Gly-Arg]+Na]+, 892.4 [M−furan−[Cys(StBu)-Gly-Arg]+K]+; M 
calcd for C45H59N9O12S 949.4, M−furan calcd for C39H51N9O11S 853.3. 
 
Deprotection of the maleimide of 5. 5 (100 nmol) was dissolved in H2O/MeOH (4 
mL) to yield a 25 µM solution, which was heated in a MW oven as described above 
(General Methods). Two different products, namely 6 and 7, were obtained (no trace of 
5 was detected in any case), in a ratio that varied depending on the reaction time: the 6:7  
 ratio was 49:51 after 30 min heating, 56:44 after 60 min, and 59:41 after 90 min. 6 And 
7 were separated using analytical acidic HPLC conditions, and characterized by 
MALDI-TOF MS before and after reaction with thrombin (see below). For an additional 
proof of structure, samples of 6 and 7 were subsequently reacted as described below to 
yield compounds 16 and 8, respectively, which were also characterized by MS. 
 
Cyclic H-Cys(StBu)-Gly-Arg-Gly-Cys*-Tyr-Ala-Tyr-Lys*-NH2, 6. Analytical 
HPLC: acidic conditions, linear gradient from 5 to 50% of B in 30 min, tR = 20.1 min. 
MALDI-TOF MS (DHB, positive mode): m/z 1258.9 [M+H]+, 1280.9 [M+Na]+, 1296.8 
[M+K]+; M calcd for C54H79N15O14S3 1257.5. MALDI-TOF MS after reaction with 
H2O2 (DHB, positive mode): m/z 1186.7 [M−StBu+16+H]+, 1234.7 
[M−StBu+16+48+H]+, 1290.7 [M+32+H]+; M+32 calcd for C54H79N15O16S3 1289.5, 
M−StBu+16 calcd for C50H71N15O15S2 1185.5. MALDI-TOF MS after reaction with 
thrombin (DHB, positive mode): m/z 876.4 [M−[Cys(StBu)-Gly-Arg]+Na]+, 892.4 
[M−[Cys(StBu)-Gly-Arg]+K]+; M−[Cys(StBu)-Gly-Arg] calcd for C39H51N9O11S 853.3. 
 
Cyclic H-Cys-Gly-Arg-Gly-Cys*-Tyr-Ala-Tyr-Lys*-NH2, 16. Compound 6 (67 
nmol) was reacted with TCEP according to the general procedures. Compound 16 was 
obtained in 76% yield (based on the HPLC trace). Analytical HPLC: acidic conditions, 
linear gradient from 5 to 50% of B in 30 min, tR = 16.1 min. MALDI-TOF MS (DHB, 
positive mode): m/z 1170.7 [M+H]+, 1192.7 [M+Na]+, 1208.7 [M+K]+; M calcd for 
C50H71N15O14S2 1169.5. MALDI-TOF MS after reaction with H2O2 (DHB, negative 
mode): m/z 1232.6 [M+48+16−H]-; M+48+16 calcd for C50H71N15O18S2 1233.5. 
MALDI-TOF MS after digestion with thrombin (DHB, positive mode): m/z 876.5 
 [M−[Cys-Gly-Arg]+Na]+, 892.5 [M−[Cys-Gly-Arg]+K]+; M−[Cys-Gly-Arg] calcd for 
C39H51N9O11S 853.4. 
 
Cyclic H-Cys*-Gly-Arg-Gly-Cys*-Tyr-Ala-Tyr-Lys(Prot.Mal.)-NH2, 7. Analytical 
HPLC: acidic conditions, linear gradient from 5 to 50% of B in 30 min, tR = 16.7 min. 
MALDI-TOF MS (DHB, positive mode): m/z 1168.8 [M+H]+, 1190.7 [M+Na]+, 1206.7 
[M+K]+; M calcd for C50H69N15O14S2 1167.5. MALDI-TOF MS after reaction with 
H2O2 (DHB, negative mode): m/z 1264.7 [M+48+48−H]-, M+48+48 calcd for 
C50H71N15O20S2 1265.4. MALDI-TOF MS after digestion with thrombin (DHB, positive 
mode): m/z 1168.8 [M+H]+, 1190.7 [M+Na]+, 1206.7 [M+K]+; M calcd for 
C50H69N15O14S2 1167.5. No digestion was detected. 
 
Conjugate 8, [cyclic H-Cys*-Gly-Arg-Gly-Cys*-Tyr-Ala-Tyr-Lys(Mal.)-NH2] + 
[diene-dT5]. 7 (15 nmol) and diene-dT5 (25 nmol) were dissolved in water (65 µL), and 
allowed to react overnight at room temperature, yielding the desired product 8 (8.8 
nmol, 59% conjugation and purification yield). 8 Was purified using acidic analytical 
HPLC conditions. Analytical HPLC: buffered medium, linear gradient from 5 to 60% of 
B in 30 min, tR = 23.0 min. MALDI-TOF MS (THAP, negative mode): m/z 2785.0 
[M−H]-, 2822.9 [M−2H+K]-; M calcd for C106H144N25O50P5S2 2785.8. 
 
H-Cys(Acm)-Gly-Arg-Gly-Cys-Tyr-Ala-Tyr-Lys(Prot.Mal.)-NH2, 10. Fmoc-
Cys(Acm)-OH was incorporated onto 34 µmol of peptide-resin Fmoc-Gly-Arg(Pbf)-
Gly-Cys-Tyr(tBu)-Ala-Tyr(tBu)-Lys(Prot.Mal.)-resin, and the Fmoc group removed to 
yield 9. Treatment with TFA/TIS/H2O 95:2.5:2.5, 2 × 1 h, and purification at the 
semipreparative scale (linear gradient from 25 to 70% of B in 30 min, tR = 6.2 min) 
 afforded a white solid corresponding to the desired peptide 10 (11.4 µmol, 34%). 
Analytical HPLC: acidic conditions, linear gradient from 5 to 50% of B in 30 min, tR = 
19.0 min. MALDI-TOF MS (DHB, positive mode): m/z 1170.7 [M−furan−Acm+H]+ 
1241.8 [M−furan+H]+; M calcd for C59H84N16O16S2 1336.6, M−furan calcd for 
C53H76N16O15S2 1240.5. MALDI-TOF MS after reaction with H2O2 (DHB, negative 
mode): m/z 1169.0 [M−furan−Acm-H]-, 1217.0 [M−furan−Acm+48−H]-, 1233.0 
[M−furan−Acm+48+16−H]-; M+48 calcd for C59H84N16O19S2 1384.5, 
M−furan−Acm+48 calcd for C50H71N15O17S2 1217.5. 
 
Cyclic H-Cys(Acm)-Gly-Arg-Gly-Cys*-Tyr-Ala-Tyr-Lys*-NH2, 11. Compound 10 
(100 nmol) was dissolved in the H2O/MeOH mixture (1 mL, 100 µM) and heated in a 
MW oven according to the general procedures, yielding the desired product 11 (30 
nmol, 30% cyclization and purification yield). 11 Was purified using acidic analytical 
HPLC conditions. Analytical HPLC: acidic conditions, linear gradient from 5 to 50% of 
B in 30 min, tR = 16.0, 16.2 min (2 diastereomers). MALDI-TOF MS (DHB, positive 
mode): m/z 1241.7 [M+H]+, 1263.7 [M+Na]+, 1279.7 [M+K]+; M calcd for 
C53H76N16O15S2 1240.5. MALDI-TOF MS after reaction with H2O2 (DHB, positive 
mode): m/z 1203.2 [M−Acm+32+H]+; M+32 calcd for C53H76N16O17S2 1272.5, 
M−Acm+32 calcd for C50H71N15O16S2 1201.6. 
 
Assays to remove the Acm group from peptide 11.  
Reaction with AgOTf. Compound 11 (30 nmol) was dissolved in TFA (1 mL), and 
AgOTf (1 mg, 3.9 µmol) and anisole (430 µL, 3.9 µmol) were added. The mixture was 
allowed to react for 1 h, after which time solvent was removed under reduced pressure 
and the crude redissolved with DTT (1 mg, 6.5 µmol) in a 1:1 mixture of H2O:AcOH 
 (1.5 mL). After 30 min, the solution was frozen and lyophilized. The crude was then 
redissolved in water and analyzed, yielding a very complex HPLC profile. Integration 
of the HPLC trace and MALDI-TOF MS analysis showed that the desired product was 
obtained in less than 5% yield. 
Reaction with I2. Compound 11 (500 nmol) was dissolved in a 9:1 H2O:AcOH mixture 
(100 µL) and I2 (100 µL of a 50 mM solution in MeOH) was added. The mixture was 
allowed to react for 4 h. The reaction was quenched with 0.2 M sodium ascorbate (20 
µL), and methanol was removed under reduced pressure. Neither HPLC analysis nor 
MALDI-TOF MS of the crude showed the presence of the desired product, but one 
resulting from the addition of 1 – 4 iodines to the peptide. 
Reaction with Tl(OAc)3. Compound 11 (50 nmol) was dissolved in TFA (500 µL), and a 
solution of Tl(OAc)3 (390 µg, 100 nmol) and anisole (10.9 µL, 100 nmol) in TFA (10 
µL) was added. The mixture was reacted for 1 h at 0 ºC, and the solvent was removed 
with a N2 stream. 10% Acetic acid in water (1 mL) and chloroform (1 mL) were added, 
and the two fractions were collected separately. HPLC and MALDI-TOF analysis of the 
two fractions showed the presence of multiple products, none of which could be 
identified. 
 
H-Cys(Fm)-Gly-Arg-Gly-Cys-Tyr-Ala-Tyr-Lys(Prot.Mal.)-NH2, 13. Boc-Cys(Fm)-
OH was incorporated onto 31 µmol of Fmoc-Gly-Arg(Pbf)-Gly-Cys(Tr)-Tyr(tBu)-Ala-
Tyr(tBu)-Lys(Prot.Mal.)-resin. Treatment with TFA/TIS/H2O 95:2.5:2.5, 2 × 1 h, and 
purification at the semipreparative scale (linear gradient from 30 to 60% of B in 30 min, 
tR = 9.5 min) afforded a white solid corresponding to the desired peptide 13 (9.6 µmol, 
31%). Analytical HPLC: acidic conditions, linear gradient from 30 to 60% of B in 30 
min, tR = 7.0 min. MALDI-TOF (DHB, positive mode): m/z 1348.9 [M−furan+H]+, 
 1370.8 [M−furan+Na]+, 1386.8 [M−furan+K]+; M calcd for C70H89N15O15S2 1443.6, 
M−furan calcd for C64H81N15O14S2 1347.6. MALDI-TOF MS after reaction with H2O2 
(DHB, negative mode): m/z 1214.4 [M−furan−Fm+48−H]- 1232.6 
[M−furan−Fm+48+16−H]-; M+48+16 calcd for C70H89N15O19S2 1507.6, 
M−furan−Fm+48+16 calcd for C50H71N15O18S2 1233.5. 
 
Cyclic H-Cys(Fm)-Gly-Arg-Gly-Cys*-Tyr-Ala-Tyr-Lys*-NH2, 14. 13 (400 nmol) 
was dissolved in the H2O/MeOH mixture (4 mL, 100 µM), heated in a MW oven 
according to the general procedures, and purified using analytical HPLC conditions to 
yield 14 (184 nmol, 46% cyclization and purification yield). Analytical HPLC: acidic 
conditions, linear gradient from 30 to 60% of B in 30 min, tR = 4.8 min. MALDI-TOF 
MS (DHB, positive mode): m/z 1348.8 [M+H]+, 1370.8 [M+Na]+, 1386.7 [M+K]+; M 
calcd for C64H81N15O14S2 1347.6. MALDI-TOF after reaction with H2O2 (DHB, 
positive mode): m/z 1202.7 [M−Fm+32+H]+, 1380.9 [M+32+H]+; M+32 calcd for 
C64H81N15O16S2 1379.5. 
 
Disulfide dimer of cyclic H-Cys-Gly-Arg-Gly-Cys*-Tyr-Ala-Tyr-Lys*-NH2, 15. 14 
(92 nmol) was dissolved in 33% piperidine in DCM (500 µL), and the mixture reacted 
for 45 min. The solvent was then removed under reduced pressure, and coevaporations 
with acetonitrile. The crude was purified using analytical HPLC acidic conditions 
(linear gradient from 5 to 50% of B in 30 min, tR = 17.8 min), yielding 15 (41.6 nmol, 
45% reaction and purification yield). MALDI-TOF MS (DHB, positive mode): m/z 
1170.6 [monomer+H]+, 2338.3 [M+H]+; M calcd for C100H114N30O28S4 2336.9. 
 
 Cyclic H-Cys-Gly-Arg-Gly-Cys*-Tyr-Ala-Tyr-Lys*-NH2, 16. Compound 15 (27 
nmol) was reacted with TCEP as described above. Compound 16 was obtained in 89% 
yield (based on the HPLC trace) and purified using analytical HPLC conditions. 
Analytical HPLC: acidic conditions, linear gradient from 5 to 50% of B in 30 min, tR = 
15.8 min. MALDI-TOF MS (DHB, positive mode): m/z 1171.1 [M+H]+, 1193.0 
[M+Na]+; M calcd for C50H71N15O14S2 1169.5. 
 
Conjugate 17, [cyclic H-Cys-Gly-Arg-Gly-Cys*-Tyr-Ala-Tyr-Lys*-NH2] + 
[maleimido-dT5]. [Protected maleimido]-dT5 (25 nmol) was dissolved in the 1:1 
MeOH:H2O solution (1 mL, 25 µM), and heated in the microwave oven for 60 min at 
90 ºC. Methanol was removed under reduced pressure. HPLC Analysis of the crude 
(buffered medium) showed that maleimide deprotection had taken place at an 85% 
extent. This crude was used immediately for the conjugation reaction. Analytical HPLC: 
buffered medium, linear gradient from 5 to 60% of B in 30 min, tR = 18.3 min. MALDI-
TOF MS (THAP, negative mode): m/z 1661.7 [M−H]-; M calcd for C56H72N11O38P5 
1661.3. 
Mal-dT5 (5 nmol) was mixed with 16 (4 nmol) dissolved in water (375 µL) and reacted 
overnight. The desired product (17) was obtained in 73% yield (based on the HPLC 
trace). Analytical HPLC: buffered medium, linear gradient from 5 to 60% of B in 30 
min, tR = 22.0 min. MALDI-TOF MS (THAP, negative mode): m/z 2830.2 [M−H]-; M 
calcd for C106H143N26O52P5S2 2830.8. 
 
Cyclic Lys*-Gly-Arg-Gly-Cys(StBu)-Tyr-Ala-Tyr-Cys*-NH2, 19. The synthesis of 
18 was carried out on 110 mg of resin (f = 0.65 mmol/g). After reaction with 
TFA/TIS/H2O 90:5:5, 2 × 1 h, and purification at the semipreparative scale (linear 
 gradient from 25 to 50% of B in 30 min, tR = 9.8 min), 19 was obtained as a white solid 
(8.7 µmol, 11%). Analytical HPLC: acidic conditions, linear gradient from 20 to 60% of 
B in 30 min, tR = 11.7 min. MALDI-TOF MS (DHB, positive mode): m/z 1259.1 
[M+H]+; M calcd for C54H79N15O14S3 1257.5. MALDI-TOF MS after reaction with 
H2O2 (DHB, positive mode): m/z 1186.6 [M−StBu+16+H]+, 1306.7 [M+32+16+H]+; 
M−StBu+16 calcd for C50H71N15O15S2 1185.5; M+32+16 calcd for C54H79N15O17S3 
1305.5. MALDI-TOF MS after digestion with thrombin (DHB, positive mode): m/z 
1259.2 [M+H]+, 1281.2 [M+Na]+, 1297.2 [M+K]+; M calcd for C54H79N15O14S3 1257.5. 
No digestion was observed. 
 
Cyclic Lys*-Gly-Arg-Gly-Cys-Tyr-Ala-Tyr-Cys*-NH2, 20. Compound 19 (100 
nmol) was reacted with as described above (General Methods). Compound 20 was 
obtained in 80% yield (based on the HPLC trace) and purified using acidic analytical 
HPLC conditions. Analytical HPLC: acidic conditions, linear gradient from 10 to 50% 
of B in 30 min. tR = 13.5 min. MALDI-TOF MS (DHB, positive mode): m/z 1170.9 
[M+H]+; M calcd for C50H71N15O14S2 1169.5. 
 
Conjugate 21, [cyclic Lys*-Gly-Arg-Gly-Cys-Tyr-Ala-Tyr-Cys*-NH2] + 
[maleimido-dT5]. 20 (10 nmol) and [Protected maleimido]-dT5 (10 nmol) were 
dissolved in a 3:1 MeOH:H2O solution (500 µL, 20 µM), and heated in a MW oven for 
90 min at 90 oC. Methanol was removed under reduced pressure. The desired product 
(21) was obtained in 77% yield (based on the HPLC trace). Analytical HPLC: buffered 
medium, linear gradient from 5 to 50% of B in 30 min, tR = 14.9 min. MALDI-TOF MS 
(THAP, negative mode): m/z 2829.5 [M−H]-; M calcd for C106H143N26O52P5S2 2830.7. 
 
 [Protected maleimido]-[N-(CH2CH2NH2)Gly]-[N-(CH2CH2Phenol)Gly]-[N-
(CH2CH2OH)Gly]-[N-(Propargyl)Gly]-[N-(CH2CH2Phenol)Gly]-[N-
(CH2CH2NH2)Gly]-[N-(CH2CH2OH)Gly]-[N-(CH2CH2SH)Gly]-Gly-NH2, 23. 
Peptoid 23 was assembled on 100 mg of resin (f = 0.72 mmol/g). Treatment of the 
peptoid-resin 22 with TFA/m-cresol/TIS/H2O 90:5:2.5:2.5, 2 × 1 h, followed by 
purification at the semipreparative scale (linear gradient from 20 to 40% of B in 30 min, 
tR = 12.0 min), afforded 23 as a white solid (3.0 µmol, 4.1%). Analytical HPLC: acidic 
conditions, linear gradient from 20 to 40% of B in 30 min, tR = 9.7 min. MALDI-TOF 
MS (THAP/CA, positive mode): m/z 1194.7 [M−furan+H]+, 1290.8 [M+H]+; M calcd 
for C60H83N13O17S 1289.6, M−furan calcd for C54H75N13O16S 1193.5. MALDI-TOF MS 
after reaction with H2O2 (THAP/CA, negative mode): m/z 1240.7 [M−furan+48-H]-; 
M−furan+48 calcd for C54H75N13O19S 1241.5. 
 
Cyclic maleimido*-[N-(CH2CH2NH2)Gly]-[N-(CH2CH2Phenol)Gly]-[N-
(CH2CH2OH)Gly]-[N-(Propyne)Gly]-[N-(CH2CH2Phenol)Gly]-[N-
(CH2CH2NH2)Gly]-[N-(CH2CH2OH)Gly]-[N-(CH2CH2SH)Gly]*-Gly-NH2 24. 23 
(100 nmol) was dissolved in the H2O/MeOH solution (1 mL, 100 µM) and heated in a 
MW oven according to the general procedures. MeOH was removed under reduced 
pressure. The desired product (24) was obtained in 79% yield (based on the HPLC 
trace). Analytical HPLC: acidic conditions, linear gradient from 20 to 40% of B in 30 
min, tR = 15.8 min. MALDI-TOF MS (THAP/CA, positive mode): m/z 1194.7 [M+H]+; 
M calcd for C54H75N13O16S 1193.5. MALDI-TOF MS after reaction with H2O2 
(THAP/CA, positive mode): m/z 1210.7 [M+16+H]+; M+16 calcd for C54H75N13O17S 
1209.5. 
 
 Conjugate 25, [cyclic maleimido*-[N-(CH2CH2NH2)Gly]-[N-(CH2CH2Phenol)Gly]-
[N-(CH2CH2OH)Gly]-[N-(Propyne)Gly]-[N-(CH2CH2Phenol)Gly]-[N-
(CH2CH2NH2)Gly]-[N-(CH2CH2OH)Gly]-[N-(CH2CH2SH)Gly]*-Gly-NH2] + AZT. 
A 0.5 mM solution of CuSO4 in water (50 µL, 25 nmol) and a 12 mM solution of 
sodium ascorbate in water (50 µL, 600 nmol) were mixed in a microwave flask under an 
Ar atmosphere, and stirred during 5 minutes. Then TBTA (tris[(1-benzyl-1H-1,2,3-
triazol-4-yl)methyl]amine) (50 µL of a 0.5 mM solution in MeOH:H2O 3:2, 24 nmol), 
AZT (3′-azido-3′-deoxythymidine) (110 µL of a 2 mM aqueous solution, 200 nmol) and 
compound 24 (100 µL of a 290 µM aqueous solution, 29 nmol) were added. The 
mixture was heated in a microwave oven for 1 h at 90 ºC. MeOH was then removed 
under reduced pressure. The desired product (25) was obtained in 90% yield (based on 
the HPLC trace, calculated from compound 24). Analytical HPLC: acidic conditions, 
linear gradient from 5 to 50% of B in 30 min, tR = 17.1 min. MALDI-TOF MS (DHB, 
positive mode): m/z: 1462.4 [M+H]+; 1484.3 [M+Na]+; M calcd for C64H88N18O20S 
1460.6. 
 
S-Trityl cysteamine hydrochloride. Trityl chloride (279 mg, 1.6 mmol) and 
cysteamine hydrochloride (200 mg, 1.8 mmol) were dissolved in DMF (1.5 mL) and 
stirred overnight at room temperature. The reaction was then quenched with cold water 
(10 mL), and the precipitated formed was filtered and washed with cold water (3 × 5 
mL). A white solid (480 mg, 85% yield) was obtained. Rf (Hexanes/AcOEt/TEA 
75:20:5) = 0.68; 1H NMR (CD3OD, 400MHz): δ 7.5 – 7.1 (m, 15H, aromatics); 2.58 (t, 
J = 6.9, 2H, CH2-NH2); 2.47 (t, J = 6.8, 2H, S-CH2) ppm; 13C NMR (CD3OD, 
100MHz): δ 145.6, 130.7, 129.2, 128.2, 68.4, 39.7, 30.1; ESI MS (positive mode): m/z 
319.9 [M+H]+, 639.0 [2M+H]+; M calcd for C21H21NS 319.14. 
  
N-Boc-ethylenediamine. A solution of Boc anhydride (1.2 g, 5.5 mmol) in DCM (80 
mL) was added dropwise during 15 minutes to a solution of ethylenediamine (2.2 mL, 
33.5 mmol) in DCM (10 mL). The mixture was stirred for 1 h at 0 ºC and overnight at 
room temperature. Solvent was removed under reduced pressure, and the crude was 
dissolved in aqueous potassium carbonate (50 mL). This solution was extracted with 
DCM (3 × 50 mL). The organic fraction was dried over MgSO4, filtered and the solvent 
removed under reduced pressure. A colorless oil (857 mg, 60% yield) was obtained. Rf 
(Hexanes/AcOEt/TEA 47.5:47.5:5) = 0.2; 1H NMR (CDCl3, 400MHz): δ 3.16 (q, J = 
5.9, 2H, CO-NH-CH2); 2.79 (t, J = 5.7, 2H, CH2-NH2); 1.44 (s, 9H, CH3) ppm; 13C 
NMR CDCl3, 100MHz): δ 156.2, 79.2, 43.2, 41.8, 28.4 ppm; ESI MS (positive mode): 
m/z: 161.13 [M+H]+; M calcd for C7H16N2O2 160.12. 
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